image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 9.31
2.2 %
$ 378 M
Market Cap
-9.22
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANGO stock under the worst case scenario is HIDDEN Compared to the current market price of 9.31 USD, AngioDynamics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANGO stock under the base case scenario is HIDDEN Compared to the current market price of 9.31 USD, AngioDynamics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANGO stock under the best case scenario is HIDDEN Compared to the current market price of 9.31 USD, AngioDynamics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANGO

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
304 M REVENUE
-10.28%
-192 M OPERATING INCOME
-900.55%
-184 M NET INCOME
-251.53%
-28.2 M OPERATING CASH FLOW
-36100.00%
124 M INVESTING CASH FLOW
1369.41%
-64.2 M FINANCING CASH FLOW
-252.75%
72 M REVENUE
-1.15%
-4.05 M OPERATING INCOME
-61.48%
-4.41 M NET INCOME
58.96%
-13.2 M OPERATING CASH FLOW
-532.11%
-3.19 M INVESTING CASH FLOW
-62.62%
7.15 M FINANCING CASH FLOW
736.42%
Balance Sheet AngioDynamics, Inc.
image
Current Assets 193 M
Cash & Short-Term Investments 76.1 M
Receivables 43.6 M
Other Current Assets 73.6 M
Non-Current Assets 124 M
Long-Term Investments 0
PP&E 41.5 M
Other Non-Current Assets 82.9 M
23.94 %13.73 %23.16 %13.05 %26.11 %Total Assets$317.7m
Current Liabilities 91.2 M
Accounts Payable 37.8 M
Short-Term Debt 1.98 M
Other Current Liabilities 51.4 M
Non-Current Liabilities 20.9 M
Long-Term Debt 3.94 M
Other Non-Current Liabilities 17 M
33.68 %45.88 %3.51 %15.16 %Total Liabilities$112.1m
EFFICIENCY
Earnings Waterfall AngioDynamics, Inc.
image
Revenue 304 M
Cost Of Revenue 149 M
Gross Profit 155 M
Operating Expenses 347 M
Operating Income -192 M
Other Expenses -8.09 M
Net Income -184 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)304m(149m)155m(347m)(192m)8m(184m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
50.90% GROSS MARGIN
50.90%
-63.32% OPERATING MARGIN
-63.32%
-60.66% NET MARGIN
-60.66%
-89.67% ROE
-89.67%
-58.03% ROA
-58.03%
-81.02% ROIC
-81.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AngioDynamics, Inc.
image
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -184 M
Depreciation & Amortization 27.7 M
Capital Expenditures -5.77 M
Stock-Based Compensation 10.5 M
Change in Working Capital 14.4 M
Others 99.9 M
Free Cash Flow -33.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AngioDynamics, Inc.
image
Wall Street analysts predict an average 1-year price target for ANGO of $16.1 , with forecasts ranging from a low of $12 to a high of $27 .
ANGO Lowest Price Target Wall Street Target
12 USD 28.89%
ANGO Average Price Target Wall Street Target
16.1 USD 73.39%
ANGO Highest Price Target Wall Street Target
27 USD 190.01%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership AngioDynamics, Inc.
image
Sold
0-3 MONTHS
50 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
136 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well. zacks.com - 1 week ago
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents. benzinga.com - 2 weeks ago
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript AngioDynamics, Inc. (NASDAQ:ANGO ) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call. seekingalpha.com - 2 weeks ago
AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates AngioDynamics (ANGO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.16 per share a year ago. zacks.com - 2 weeks ago
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights   Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sale. businesswire.com - 2 weeks ago
AngioDynamics to Host Virtual Cardiovascular Investor Event LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which wil. businesswire.com - 2 weeks ago
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into th. businesswire.com - 4 weeks ago
AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 35th Annual Healthcare MedTech and Service. businesswire.com - 1 month ago
ANGO Stock Looks Promising on New Ischemia Study for Auryon System AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease. zacks.com - 2 months ago
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Criti. businesswire.com - 2 months ago
AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. seekingalpha.com - 2 months ago
AngioDynamics price target raised to $15 from $12 at Canaccord Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability. https://thefly.com - 3 months ago
8. Profile Summary

AngioDynamics, Inc. ANGO

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 378 M
Dividend Yield 0.00%
Description AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Contact 14 Plaza Drive, Latham, NY, 12110 https://www.angiodynamics.com
IPO Date June 1, 2004
Employees 748
Officers Mr. Benjamin H. Davis Senior Vice President of Business Development & Strategy Mr. Stephen A. Trowbridge Executive Vice President & Chief Financial Officer Mr. James C. Clemmer Chief Executive Officer, President & Director Mr. Chad T. Campbell Senior Vice President & GM of Oncology and Interventional Devices Mr. Warren G. Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain Ms. Marna I. Bronfen-Moore Senior Vice President of Human Resources Mr. Saleem M. Cheeks Vice President of Communications Mr. Juan Carlos Serna Senior Vice President of Scientific & Clinical Affairs Ms. Laura Piccinini Senior Vice President & GM of Cardiovascular and International Ms. Kim L. Seabury Senior Vice President of Information Technology